Colgate-Palmolive Company (NYSE:CL) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Colgate-Palmolive Company (NYSE:CL) have earned a consensus recommendation of “Moderate Buy” from the seventeen analysts that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $94.3750.

A number of research analysts have commented on the stock. The Goldman Sachs Group reissued a “buy” rating and set a $94.00 target price on shares of Colgate-Palmolive in a research report on Saturday, January 31st. UBS Group boosted their price objective on shares of Colgate-Palmolive from $90.00 to $93.00 and gave the stock a “buy” rating in a research note on Wednesday, January 14th. Deutsche Bank Aktiengesellschaft upped their target price on Colgate-Palmolive from $83.00 to $90.00 and gave the stock a “hold” rating in a report on Monday, February 2nd. Citigroup lifted their price target on Colgate-Palmolive from $95.00 to $105.00 and gave the company a “buy” rating in a report on Monday, February 2nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Colgate-Palmolive in a research note on Wednesday, January 21st.

Colgate-Palmolive News Summary

Here are the key news stories impacting Colgate-Palmolive this week:

• Positive Sentiment: Zacks Research raised several forward earnings estimates (including FY2026 to $3.89 and FY2027 to $4.15) and lifted some quarterly targets, signaling better-than-expected longer‑term earnings progression — supportive for valuation upgrades. Zacks estimate revisions (MarketBeat)
• Positive Sentiment: Major brokers have recently raised targets and stance (Morgan Stanley to $100/overweight; JPMorgan to $97/overweight; Wells Fargo nudged its target higher), which can attract buying and help lift the stock. Analyst target changes (MarketBeat)
• Positive Sentiment: Media/TV mention — Jim Cramer highlighted Colgate’s strong growth, a visible endorsement that can spur retail interest and intraday buying. Cramer: Colgate had great growth
• Neutral Sentiment: Dividend and shareholder returns remain intact — Colgate paid the routine $0.52 quarterly dividend (annualized $2.08, ~2.2% yield); supportive for income investors but already priced in for many holders. Dividend announcement (MarketBeat)
• Neutral Sentiment: Institutional activity shows small incremental buys by several funds in Q4 (some managers added to positions), indicating steady institutional ownership (~80% held by institutions). That steady demand can limit downside but isn’t a near-term catalyst. Institutional flows (MarketBeat)
• Negative Sentiment: Significant insider selling: COO Panagiotis Tsourapas sold 15,000 shares (~$1.47M at ~$97.81), reducing his stake materially. Large insider sales can concern investors about timing or personal liquidity needs and may create short‑term selling pressure. COO Panagiotis Tsourapas sells 15,000 shares
• Negative Sentiment: Another insider (John Hazlin) sold ~20,989 shares for ~$1.98M. Multiple insider sales over days amplify the negative signal versus isolated transactions. Investors should watch future filings for patterns. Insider sale: John Hazlin

Insider Activity

In related news, insider John Hazlin sold 20,989 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $94.25, for a total transaction of $1,978,213.25. Following the completion of the transaction, the insider owned 17,645 shares in the company, valued at $1,663,041.25. The trade was a 54.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Panagiotis Tsourapas sold 35,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $94.61, for a total transaction of $3,311,350.00. Following the completion of the sale, the chief operating officer owned 10,415 shares of the company’s stock, valued at approximately $985,363.15. This trade represents a 77.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 184,683 shares of company stock worth $17,486,693 in the last quarter. 0.41% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Colgate-Palmolive

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jacobi Capital Management LLC increased its holdings in shares of Colgate-Palmolive by 5.8% in the fourth quarter. Jacobi Capital Management LLC now owns 10,543 shares of the company’s stock valued at $833,000 after purchasing an additional 581 shares during the period. CreativeOne Wealth LLC increased its holdings in Colgate-Palmolive by 7.6% in the 4th quarter. CreativeOne Wealth LLC now owns 16,087 shares of the company’s stock worth $1,271,000 after buying an additional 1,140 shares during the period. Kestra Advisory Services LLC raised its position in Colgate-Palmolive by 2.2% during the 4th quarter. Kestra Advisory Services LLC now owns 40,463 shares of the company’s stock worth $3,197,000 after buying an additional 885 shares during the last quarter. Ontario Teachers Pension Plan Board lifted its stake in Colgate-Palmolive by 7.3% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 40,234 shares of the company’s stock valued at $3,179,000 after acquiring an additional 2,732 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Colgate-Palmolive by 2.2% in the 4th quarter. The Manufacturers Life Insurance Company now owns 816,427 shares of the company’s stock valued at $64,689,000 after acquiring an additional 17,771 shares during the last quarter. Hedge funds and other institutional investors own 80.41% of the company’s stock.

Colgate-Palmolive Stock Up 0.5%

Shares of NYSE CL opened at $96.61 on Monday. Colgate-Palmolive has a 52-week low of $74.54 and a 52-week high of $100.18. The firm has a market capitalization of $77.87 billion, a price-to-earnings ratio of 36.87, a PEG ratio of 4.36 and a beta of 0.29. The stock has a 50 day moving average price of $83.80 and a 200 day moving average price of $81.84. The company has a debt-to-equity ratio of 5.90, a quick ratio of 0.27 and a current ratio of 0.42.

Colgate-Palmolive (NYSE:CL) last issued its earnings results on Friday, January 30th. The company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.91 by $0.04. The business had revenue of $5.23 billion during the quarter, compared to analysts’ expectations of $5.13 billion. Colgate-Palmolive had a return on equity of 353.72% and a net margin of 10.45%.The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.91 EPS. Sell-side analysts expect that Colgate-Palmolive will post 3.75 earnings per share for the current year.

Colgate-Palmolive Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, February 13th. Shareholders of record on Wednesday, January 21st were given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Wednesday, January 21st. Colgate-Palmolive’s dividend payout ratio is presently 79.39%.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.